Eli Lilly partners with Hims & Hers to sell obesity drugs via its telehealth platform
Eli Lilly and Hims & Hers announced a partnership that lets patients obtain Lilly’s obesity medicines Zepbound and Foundayo through the Hims & Hers digital‑health platform. Eligible patients receive a prescription from a licensed provider on the platform and can have the FDA‑approved drugs shipped to their homes at self‑pay prices of $299 per month for Zepbound and $149 per month for Foundayo. The deal was disclosed on 6 Nov 2026 and coincided with a rise in Hims & Hers shares and a modest decline in Lilly shares.
Why it matters
The company said the agreement expands access to its weight‑loss portfolio and supports its full‑year revenue outlook, which it raised by $5 billion. The partnership also adds a direct cash‑pay channel that could boost Lilly’s Zepbound sales, which were $5.3 billion in Q3, up 48% YoY.
Key facts
- 1The agreement was announced on 6 Nov 2026. prnewswire.com
- 2Self‑pay pricing is $149 per month for Foundayo and $299 per month for Zepbound. prnewswire.com
- 3Hims & Hers shares rose 7% in pre‑market trading after the announcement. finance.yahoo.com
- 4Lilly shares fell about 1.6% in pre‑market trading. rttnews.com
- 5Lilly raised its full‑year revenue forecast by $5 billion, citing strong demand for its weight‑loss drugs. finance.yahoo.com
- 6Lilly’s Q3 Zepbound revenue was $5.3 billion, up 48% YoY. finance.biggo.com
Summary written by AlphAI AI Desk from 20 of 24 sources. Not investment advice. Figures are as stated by the linked sources.